Halozyme Therapeutics Non-GAAP EPS of $0.82 misses by $0.01, revenue of $230.04M misses by $1.1M

• Halozyme Therapeutics press release (NASDAQ:HALO): Q4 Non-GAAP EPS of $0.82 misses by $0.01.
• Revenue of $230.04M (+26.7% Y/Y) misses by $1.1M.
• Reiterating 2024 Financial Guidance: Total revenue of $915 million to $985 million, representing growth of 10% to 19% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED^®. Revenue from royalties of $500 million to $525 million, representing growth of 12% to 17% over 2023.
• Adjusted EBITDA of $535 million to $585 million, representing growth of 26% to 37% over 2023.
• Non-GAAP diluted earnings per share of $3.55 to $3.90, representing growth of 28% to 41% over 2023.¹ The Company's earnings per share guidance does not consider the impact of potential future share repurchases.

More on Halozyme Therapeutics

• Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
• Halozyme Therapeutics Q4 2023 Earnings Preview
• EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze
• Seeking Alpha’s Quant Rating on Halozyme Therapeutics
• Historical earnings data for Halozyme Therapeutics